Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuantum Data Regulatory News (MAST)

  • There is currently no data for MAST

Broker Warrant Exercise

25 Jul 2025 07:00

RNS Number : 4893S
Mast Energy Developments PLC
25 July 2025
Β 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BNG90H86

('MED' or 'the Company')

Β 

Dated: 25 July 2025

Β 

MAST Energy Developments PLC

Β 

Exercise of Historic Broker Warrants, Issue of Equity & TVR

Β 

Mast Energy Developments PLC ("MED" or "the Company"), theΒ UK-based multi-asset owner, developer, and operator in the rapidly growing Flexible Generation Power market, announces that it has received notices of exercise for a total of 243,750 new ordinary MED shares at the exercise price of Β£0.08 (the "Broker Warrant Shares"). The broker warrants were historically issued to nominees of Novum Securities Limited on 29 May 2024, the details of which are contained in the Company's RNS announcement dated 7 May 2024. The price and number of warrants were re-stated as part of the Company's recent share capital consolidation and re-admission of its ordinary share capital, effective 14 July 2025.

Β 

Total Voting Rights

Application will be made for the admission of the 243,750 Broker Warrant Shares to trading on the LSE ("Admission") pursuant to the authorities approved by shareholders at the General Meeting held on 8 July 2025. The Shares will rank pari passu with the existing ordinary shares and it is expected that Admission will become effective at 8.00 a.m. on 30 July 2025.

Β 

Following Admission, the Company's issued share capital will consist of 13,248,927 ordinary shares with voting rights. MED Β does not hold any ordinary shares in treasury. This figure of 13,248,927 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they require to notify their interest in, or a change to their interest in, the share capital of the Company under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Β 

Following Admission, the beneficial holding of Paul Venter, non-executive director and chairman of the Company, Β will change from 15.06% to 14.79% interest in the issued share capital of the Company.

Β 

Β 

Stay up to date with MED's latest news and updates by joining our emailing list and social media channels, as follows:

Β 

MED general enquiries - https://www.med.energy/contact

MED email alerts - https://www.med.energy/rnsannoucements-1

MED LinkedIn page - https://uk.linkedin.com/company/mast-energy-developments-plc

MED X (formerly Twitter) handle - @mastplc

ENDS

Β 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Β 

Pieter KrΓΌgel

info@med.energy

Mast Energy

Developments PLC

CEO

Guy Wheatley, CFA

+44 (0)74 9398 9014

Fortified Securities

Corporate Broker

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCSEDFLLEISEIW
Date   Source Headline
11th Feb 20257:00 amRNSRecord High January Revenues
27th Jan 20257:00 amRNSNew Website Launch
13th Jan 20257:00 amRNSRecord High Sales Price Achieved
19th Dec 20247:00 amRNSCompany Update
3rd Dec 20247:00 amRNSCompany Update
22nd Nov 20247:00 amRNSOperating & Corporate Update
14th Oct 202412:30 pmRNSHolding(s) in Company
10th Oct 202412:20 pmRNSHolding(s) in Company
8th Oct 202412:30 pmRNSHolding(s) in Company
7th Oct 20247:00 amRNSRecord High September Revenues
1st Oct 20248:00 amRNSShares Lock-in Agreement & Pyebridge Update
12th Sep 20247:00 amRNSPyebridge Revenue Updates
30th Aug 20247:00 amRNSHalf-year Report
20th Aug 20247:00 amRNSBusiness Update
13th Aug 202412:30 pmRNSTR-1 Notification
8th Aug 20244:30 pmRNSTR-1 Notification
7th Aug 20247:00 amRNSPyebridge Revenue Update re Refurbished Genset
31st Jul 20243:00 pmRNSTR-1 Notification
30th Jul 20247:00 amRNSTR1 Notification
1st Jul 20247:00 amRNSRevenue Generation & Potential Acquisition
13th Jun 20247:00 amRNSBusiness Update
5th Jun 20241:22 pmRNSHolding(s) in Company
30th May 20242:00 pmRNSResult of AGM
29th May 20249:11 amRNSHolding(s) in Company
23rd May 20243:55 pmRNSCapitalisation of Loan Update
21st May 20247:00 amRNSBusiness Update
9th May 202410:45 amRNSHolding(s) in Company
8th May 20247:00 amRNSNotice of AGM
7th May 20247:00 amRNSUpdate, Loan Capitalisation & Equity Issue
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
26th Apr 20247:00 amRNSBusiness Update
23rd Apr 20242:30 pmRNSHolding(s) in Company TR 1
11th Apr 20247:00 amRNSBusiness Update
7th Mar 20248:06 amRNSQ1 2024 Corporate Presentation
4th Mar 202410:45 amRNSHolding(s) in Company
28th Feb 20247:00 amRNSFunding Partner, Agreement & Proventure Terminated
20th Feb 20241:00 pmRNSTR-1: Standard form notification of major holdings
5th Feb 20241:55 pmRNSTR-1: Standard form notification of major holdings
24th Jan 20243:45 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSMED Binding JVA Progress Update
2nd Jan 20247:00 amRNSMED Binding JVA Completion Update
22nd Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Dec 20237:00 amRNSDirector Loan & PDMR Share Sale
11th Dec 20237:52 amRNSMED Binding JVA Update
11th Dec 20237:00 amRNSMED Binding JVA Completion Update
5th Dec 20234:30 pmRNSHolding(s) in Company
1st Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Nov 20233:31 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSMED Binding JVA Interim Payment Update
26th Oct 202310:54 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.